TransCode Therapeutics Presents Phase 1a Clinical Data for TTX-MC138 at ESMO Congress 2026
Stocks in this Quantisnow insightHealth Care
Historical context for RNAZ
Across the 16 sessions after earlier RNAZ headlines, the stock closed higher 7 times and lower 7 times, with a median move of 3.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | RNAZ | SPY |
|---|---|---|---|
| Oct 19, 2026 | TransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026 | +0.0% | +0.4% |
| Sep 28, 2026 | TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up | +1.2% | -0.7% |
| Sep 22, 2026 | TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology | +0.6% | -0.0% |
| Aug 31, 2026 | TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis | -3.7% | -0.3% |
| Jun 8, 2026 | TransCode Therapeutics to Host R&D Webcast on June 18, 2026 | -9.1% | +0.2% |
| Jun 3, 2026 | TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer | -4.6% | -0.7% |
Quantisnow market dataNASDAQ
RNAZ
TransCode Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2021
Get push alerts for RNAZ
Full RNAZ profile on Quantisnow Follow RNAZ and get a push notification the moment its next story breaks.